Literature DB >> 14996747

Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress.

Ioannis P Trougakos1, Alan So, Burkhard Jansen, Martin E Gleave, Efstathios S Gonos.   

Abstract

Clusterin/Apolipoprotein J (CLU) is a heterodimeric ubiquitously expressed secreted glycoprotein that is implicated in several physiological processes and is differentially expressed in many severe physiological disturbances, including tumor formation and in vivo cancer progression. Despite extensive efforts, clarification of CLU's biological role has been exceptionally difficult and its precise function remains elusive. Short RNA duplexes, referred to as small interfering RNAs (siRNAs), provide a new approach for the elucidation of gene function in human cells. Here, we describe siRNA-mediated CLU gene silencing in osteosarcoma and prostate human cancer cells and illustrate that CLU mRNA is amenable to siRNA-mediated degradation. Our data demonstrate that CLU knockdown in human cancer cells induces significant reduction of cellular growth and higher rates of spontaneous endogenous apoptosis. Moreover, CLU knockdown cancer cells were significantly sensitized to both genotoxic and oxidative stress induced by chemotherapeutic drugs and H(2)O(2), respectively. These effects were more pronounced in cell lines that express high endogenous steady-state levels of the CLU protein and occur through hyperactivation of the cellular apoptotic machinery. Overall, our results reveal that, in the distinct cellular contexts of the osteosarcoma and prostate cancer cells assayed, CLU is a central molecule in cell homeostasis that exerts a cytoprotective function. The described CLU-specific siRNA oligonucleotides that can potently silence CLU gene expression may thus prove valuable agents during antitumor therapy or at other pathological conditions where CLU has been implicated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996747     DOI: 10.1158/0008-5472.can-03-2664

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  74 in total

1.  CRM1 protein-mediated regulation of nuclear clusterin (nCLU), an ionizing radiation-stimulated, Bax-dependent pro-death factor.

Authors:  Konstantin S Leskov; Shinako Araki; John-Paul Lavik; Jose A Gomez; Vivian Gama; Efstathios S Gonos; Ioannis P Trougakos; Shigemi Matsuyama; David A Boothman
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

2.  Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.

Authors:  Bin Zhong; David A Sallman; Danielle L Gilvary; Daniele Pernazza; Eva Sahakian; Dillon Fritz; Jin Q Cheng; Ioannis Trougakos; Sheng Wei; Julie Y Djeu
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

3.  The role of stress proteins in prostate cancer.

Authors:  Alan So; Boris Hadaschik; Richard Sowery; Martin Gleave
Journal:  Curr Genomics       Date:  2007-06       Impact factor: 2.236

4.  Increased clusterin expression in Fuchs' endothelial dystrophy.

Authors:  Ula V Jurkunas; Maya S Bitar; Ian Rawe; Deshea L Harris; Kathryn Colby; Nancy C Joyce
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-03-31       Impact factor: 4.799

Review 5.  Clusterin and chemoresistance.

Authors:  Julie Y Djeu; Sheng Wei
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

Review 6.  Tumor-associated antigen arrays for the serological diagnosis of cancer.

Authors:  Carlos A Casiano; Melanie Mediavilla-Varela; Eng M Tan
Journal:  Mol Cell Proteomics       Date:  2006-05-29       Impact factor: 5.911

7.  Clusterin in Neuroendocrine Epithelial Neoplasms: Absence of Expression in a Well-differentiated Tumor Suggests a Jejunoileal Origin.

Authors:  Thomas W Czeczok; Kristen M Stashek; Jessica E Maxwell; Thomas M O'Dorisio; James R Howe; Jason L Hornick; Andrew M Bellizzi
Journal:  Appl Immunohistochem Mol Morphol       Date:  2018-02

8.  Clusterin and chemotherapy sensitivity under normoxic and graded hypoxic conditions in colorectal cancer.

Authors:  David Kevans; Sheeona Gorman; Miriam Tosetto; Kieran Sheahan; Diarmuid O'Donoghue; Hugh Mulcahy; Jacintha O'Sullivan
Journal:  J Gastrointest Cancer       Date:  2012-06

Review 9.  Clusterin and DNA repair: a new function in cancer for a key player in apoptosis and cell cycle control.

Authors:  B Shannan; M Seifert; D A Boothman; W Tilgen; J Reichrath
Journal:  J Mol Histol       Date:  2006-09-19       Impact factor: 2.611

10.  Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth.

Authors:  Vera Chesnokova; Svetlana Zonis; Kolja Wawrowsky; Yuji Tani; Anat Ben-Shlomo; Vladimir Ljubimov; Adam Mamelak; Serguei Bannykh; Shlomo Melmed
Journal:  Mol Endocrinol       Date:  2012-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.